Literature DB >> 32181817

Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.

LiQi Li1, Apratim Mitra2, Kairong Cui3, Bin Zhao1, Seeyoung Choi1, Jan Y Lee1, Daniel B Stamos1, Dalal El-Khoury1, Claude Warzecha1, Karl Pfeifer2, Joyce Hardwick4,5, Keji Zhao3, Bryan Venters4, Utpal P Davé4,5, Paul E Love1.   

Abstract

Prolonged or enhanced expression of the proto-oncogene Lmo2 is associated with a severe form of T-cell acute lymphoblastic leukemia (T-ALL), designated early T-cell precursor ALL, which is characterized by the aberrant self-renewal and subsequent oncogenic transformation of immature thymocytes. It has been suggested that Lmo2 exerts these effects by functioning as component of a multi-subunit transcription complex that includes the ubiquitous adapter Ldb1 along with b-HLH and/or GATA family transcription factors; however, direct experimental evidence for this mechanism is lacking. In this study, we investigated the importance of Ldb1 for Lmo2-induced T-ALL by conditional deletion of Ldb1 in thymocytes in an Lmo2 transgenic mouse model of T-ALL. Our results identify a critical requirement for Ldb1 in Lmo2-induced thymocyte self-renewal and thymocyte radiation resistance and for the transition of preleukemic thymocytes to overt T-ALL. Moreover, Ldb1 was also required for acquisition of the aberrant preleukemic ETP gene expression signature in immature Lmo2 transgenic thymocytes. Co-binding of Ldb1 and Lmo2 was detected at the promoters of key upregulated T-ALL driver genes (Hhex, Lyl1, and Nfe2) in preleukemic Lmo2 transgenic thymocytes, and binding of both Ldb1 and Lmo2 at these sites was reduced following Cre-mediated deletion of Ldb1. Together, these results identify a key role for Ldb1, a nonproto-oncogene, in T-ALL and support a model in which Lmo2-induced T-ALL results from failure to downregulate Ldb1/Lmo2-nucleated transcription complexes which normally function to enforce self-renewal in bone marrow hematopoietic progenitors.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32181817      PMCID: PMC7316212          DOI: 10.1182/blood.2019000794

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression.

Authors:  S Herblot; A M Steff; P Hugo; P D Aplan; T Hoang
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

2.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

3.  Nuclear LIM interactor, a rhombotin and LIM homeodomain interacting protein, is expressed early in neuronal development.

Authors:  L W Jurata; D A Kenny; G N Gill
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development.

Authors:  A J Warren; W H Colledge; M B Carlton; M J Evans; A J Smith; T H Rabbitts
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

Review 5.  The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia.

Authors:  David J Curtis; Matthew P McCormack
Journal:  Clin Cancer Res       Date:  2010-09-22       Impact factor: 12.531

6.  Controlling long-range genomic interactions at a native locus by targeted tethering of a looping factor.

Authors:  Wulan Deng; Jongjoo Lee; Hongxin Wang; Jeff Miller; Andreas Reik; Philip D Gregory; Ann Dean; Gerd A Blobel
Journal:  Cell       Date:  2012-06-08       Impact factor: 41.582

7.  The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells.

Authors:  G G Grütz; K Bucher; I Lavenir; T Larson; R Larson; T H Rabbitts
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

8.  The LMO1 and LDB1 proteins interact in human T cell acute leukaemia with the chromosomal translocation t(11;14)(p15;q11).

Authors:  V Valge-Archer; A Forster; T H Rabbitts
Journal:  Oncogene       Date:  1998-12-17       Impact factor: 9.867

9.  T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes.

Authors:  P Fisch; T Boehm; I Lavenir; T Larson; J Arno; A Forster; T H Rabbitts
Journal:  Oncogene       Date:  1992-12       Impact factor: 9.867

10.  A positive role for NLI/Ldb1 in long-range beta-globin locus control region function.

Authors:  Sang-Hyun Song; Chunhui Hou; Ann Dean
Journal:  Mol Cell       Date:  2007-12-14       Impact factor: 17.970

View more
  3 in total

1.  LDB1 Enforces Stability on Direct and Indirect Oncoprotein Partners in Leukemia.

Authors:  Justin H Layer; Michael Christy; Lindsey Placek; Derya Unutmaz; Yan Guo; Utpal P Davé
Journal:  Mol Cell Biol       Date:  2020-05-28       Impact factor: 4.272

2.  LIM-Domain-Binding Protein 1 Mediates Cell Proliferation and Drug Resistance in Colorectal Cancer.

Authors:  Mo Zhu; Baofei Jiang; Hao Zuo; Xiaopeng Wang; Hengfa Ge; Ziming Huang
Journal:  Front Surg       Date:  2022-01-06

3.  Key sunitinib-related biomarkers for renal cell carcinoma.

Authors:  Yun Peng; Shiqiang Dong; Yuxuan Song; Dingkun Hou; Lili Wang; Bowen Li; Haitao Wang
Journal:  Cancer Med       Date:  2021-08-17       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.